Harnessing the Power of Dendritic Cell Therapy in the Fight Against Brain Cancer
This post explores how dendritic cell therapy leverages the immune system to combat brain cancer, particularly glioblastoma. It highlights the method of using activated dendritic cells to trigger a targeted immune response against cancer cells, showing promising clinical outcomes in extending patient survival and improving quality of life.
Michael (Germany)
Michael (Germany) Prostate CancerDCT https://vimeo.com/919539677?share=copy “In 2016, I was faced with the devastating diagnosis of advanced prostate cancer, for which conventional treatments were no longer an option. This diagnosis initially felt like an insurmountable judgement. However, my curiosity and interest in the immune system led me to discover immunotherapy as a glimmer of hope. Despite […]
Fred (Netherlands)
Fred (Netherlands) Colon CancerDCT I was diagnosed with colon cancer in September 2021.When I received this diagnosis, I admit I was initially shaken. However, I held onto hope that the standard medical treatments available in the Netherlands would be effective. Despite undergoing chemotherapy and weekly hypothermia sessions, the cancer persisted, spreading to my lungs and […]
Alicia (Romania)
Alicia (Romania) Breast CancerDCT My journey with cancer started in 2021 and for anyone who receives this news, it is groundbreaking. I took a deep breath and went forward with chemotherapy, surgery and radiotherapy. For a year, I was fine, but as my breast cancer is the most aggressive (TNBC) it came back with metastasis. […]
Matthew (USA)
Matthew (USA) Brain TumourDCT I had a meeting with the oncologist to discuss the MRI report and tumor images. During the session, we observed that the two bigger tumors had “imploded,” indicating that they have vanished, while the smaller ones have reduced to roughly half the size recorded three months ago. Additionally, there are no […]
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
This post outlines a Phase I/II clinical trial evaluating DCVAC/PCa, a dendritic cell-based immunotherapy, in combination with chemotherapy for treating metastatic castration-resistant prostate cancer. It reports that this therapy, combined with docetaxel and prednisone, showed promising safety and efficacy results, improving overall survival and inducing specific immune responses without serious adverse effects.
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer
The post discusses a study on combining high-dose chemotherapy with adoptive cellular therapy using dendritic and cytokine-induced killer cells for metastatic breast cancer. This combination showed significant improvements in progression-free and overall survival compared to chemotherapy alone, highlighting the potential of integrating immunotherapy with chemotherapy for better patient outcomes.
Sophie (UK)
Sophie (UK) Breast cancer DCT The news of my cancer diagnosis came as a shock to me. I had been diagnosed previously, but it was a different type of cancer, separated by a 16-year gap. After undergoing chemotherapy, which didn’t agree with me, I looked into radiotherapy as an alternative, only to be told it […]
Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC)
The post highlights a study showing that high levels of plasmacytoid dendritic cell (pDC) infiltration correlate with improved survival and stronger anti-cancer immune responses in triple-negative breast cancer (TNBC) compared to conventional dendritic cells (cDC). The findings suggest that pDC presence may serve as a better prognostic marker for TNBC patients.
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
The post discusses a personalized neoantigen-pulsed dendritic cell vaccine for advanced lung cancer. This innovative treatment aims to activate the immune system to target cancer cells by using neoantigens specific to each patient. The study demonstrates that this vaccine is feasible, safe, and capable of inducing a specific T-cell response, showing promising results in improving progression-free and overall survival rates in patients.
